Department of Hematology & Hematopoietic Cell Transplantation, Saul Priceman, Ph.D. Receiving a $9.28 million award from the California Institute for Regenerative Medicine (CIRM), this study will implement a HER2-specific CAR T cell therapy for metastatic breast cancer patients. By offering a new avenue for treatment, this grant further supports the development of a promising therapy for these patients that have no alternative options.City of Hope is accelerating the development of treatment options for patients with breast cancer who have challenging tumors and poor prognosis. A recent study that highlights this work is being carried out by our dedicated researcher and assistant professor in the
This is a phase 1 trial that is enrolling patients with refractory HER2-positive breast cancer with brain metastases to test the safety and effectiveness of CAR T cell therapy. For this trial, patients' re-engineered T cells will be introduced as CAR T cells directly into the brain, a procedure only attempted successfully for the first time at City of Hope.
“Our team’s goal is to develop a novel therapy for breast cancer patients with brain metastases who currently have no other effective treatments,” Priceman said.
Leading the CAR T cell trial is Jana Portnow, M.D., an associate clinical professor in the Department of Medical Oncology & Therapeutics Research and associate director of the Brain Tumor Program, along with Priceman, who conducted the preclinical research that led to the trial’s development.